1. Moving Into Uncharted Territory in Unresectable HCC: Practical Treatment Updates

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Overview

4. Treatment Options for Patients With HCC

5. Sorafenib in Advanced HCC: OS in SHARP vs Asia-Pacific Studies

6. Recent Developments in Treatment

7. Tivantinib

8. Tremelimumab

9. Nivolumab

10. Other Investigational Agents

11. Regorafenib -- RESORCE: Trial Design

12. RESORCE: Trial Results

13. RESORCE: TEAEs

14. REACH: Study Design

15. OS of ITT Population

16. OS in Patients With Baseline AFP 400 or < 400 ng/mL

17. PFS in Patients With Baseline AFP 400 ng/mL

18. Looking Ahead

19. Abbreviations

20. Abbreviations (cont)